Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing ...

After the slimming effect of Ozempic and Zepbound earned billions for Novo Nordisk and Eli Lilly, another class of weight-loss drugs called amylins is drawing the drug industry’s attention and dollars ...

AbbVie is licensing rights to a drug from Gubra that has encouraging early clinical data in obesity. The once-weekly injectable peptide is a dual agonist of the amylin and calcitonin receptors ...

Looking for successors to the blockbuster GLP-1 obesity drugs, companies like Novo Nordisk and Eli Lilly are testing amylin hormone receptor treatments. The hope is for less nausea and muscle loss.

Summary. AbbVie Inc. entered the obesity market by in-licensing GUBamy, a long-acting amylin analog, a modest but important first step to challenge Eli Lilly and Novo Nordisk.

Now scientists think they know where it goes : Shots - Health News The brain appears to rely on synchronized waves to wash out waste products, including toxins associated with Alzheimer's disease.